A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity

Cancer Gene Therapy

Volumn 10, Issue 11, 2003, Pages 823-832

  London, Carla A ^a   Sekhon, Harmanjatinder S ^b   Arora, Vikram ^a   Stein, David A ^a   Iversen, Patrick L ^a   Devi, Gayathri R ^a  

^a AVI BIOPHARMA INC   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antisense; DU145; IGF; IGFBP 3; MMP; Morpholino; Prostate

Indexed keywords

ANTISENSE PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; GELATINASE B INHIBITOR; GELATINASE INHIBITOR; MORPHOLINE DERIVATIVE; OLIGOMER; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOGENICITY TESTS; CELL SURVIVAL; ENZYME INHIBITORS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0242658826     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700642     Document Type: Article

References (48)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics (2001). CA: Cancer J Clin. 2001;51:15-36.
2. Richie JP. Anti-androgens and other hormonal therapies for prostate cancer. Urology. 1999;54:15-18.
3. Devi GR. Prostate cancer: status of current treatments and emerging antisense-based therapies. Curr Opin Mol Ther. 2002;4:138-148.
4. Sadar MD, Hussain M, Bruchovsky N. Prostate cancer: molecular biology of early progression to androgen independence. Endocrin Rel Cancer. 1999;6:487-502.
5. Overall CM. Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol Biotechnol. 2002;22:51-86.
6. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 2001;89:201-210 (Review).
7. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans. 2002;30:120-126.
8. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost. 2001;86:324-333. (Review).
9. Harada H, Furuya M, Ishikura H, Shindo J, Koyanagi T, Yoshiki T. Expression of matrix metalloproteinase in the fluids of renal cystic lesions. J Urol. 2002;168:19-22.
10. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol. 2002;127:393-398.
11. Giannelli G, Antonaci S. Gelatinases and their inhibitors in tumor metastasis: from biological research to medical applications. Histol Histopathol. 2002;17:339-345.
12. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161-174.
13. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J Cancer Res Clin Oncol. 1991;117:144-150.
14. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res. 1993;53:4493-4498.
15. Stearns ME, Wang M. Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res. 1993;53:878-883.
16. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17: 463-516.
17. Rajah R, Valentinis B, Cohen P. IGFBP-3 induces apoptosis and mediates the effects of transforming growth factor-b1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272: 12181-12188.
18. Devi GR, Sprenger C, Graham D, Plymate S, Rosenfeld RG. Overexpression of IGFBP-3 induces cell growth inhibition and early apoptosis in malignant human prostate cancer cells. Prostate 2002;53:200-210.
19. Cohen P, Peehl D, Graves H, Rosenfeld R. Biological effects of prostate specific antigen (PSA) as an IGF binding protein-3 (IGFBP-3) protease. J Endocrinol. 1994;142: 407-415.
20. Smith GL, Doherty AP, Mitchell H, Hanham IW, Christmas TJ, Epstein RJ. Inverse relation between prostate-specific antigen and insulin-like growth factor-binding protein 3 in bone metastases and serum of patients with prostate cancer. Lancet. 1999;354:2053-2054.
21. Shariat SF, Lamb DJ, Kattan MW et al. Association of preoperative plasma levels of insulin-like growth factor 1 and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol. 2002;20:833-841.
22. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 2000;19:6642-6650.
23. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002;2:657-672.
24. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acids Drug Dev. 1997;7:187-195.
25. Hudziak RM, Summerton J, Weller DD, Iversen PL. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acids Drug Dev. 2000;10:163-176.
26. Devi GR, Oldenkamp JR, London CA, Iversen PL. Inhibition of human chorionic gonadotropin beta subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 2002;53:200-210.
27. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000;60:4629-4637.
28. Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett. 1999;135:107-112.
29. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin Dl induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther. 2002;9:807-812.
30. Iversen PL, Arora V, Acker AJ, Mason D, Devi GR. Efficacy of antisense Morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin Cancer Res. 2003;9:2510-2519.
31. Desai SB, Libutti SK. Tumor angiogenesis and endothelial cell modulatory factors. J Immunother. 1999;22: 186-211.
32. Folkman J. Angiogenesis-dependent diseases. Semin Oncol. 2001;28:536-542.
33. Lokeshwar BL. MMP inhibition in prostate cancer. Ann NY Acad Sci. 1999;878:271-289 (Review).
34. Martes S, Llorente M, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez AC. The matrix metalloproteinase-9 regulates the insulin-like growth factor-triggered autocrine response in DU-145 carcinoma cells. J Biol Chem. 1999;274:6935-6945.
35. Angelloz-Nicoud P, Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology. 1995;136:5485-5492.
36. Devi GR, Yang DY, Rosenfeld RG, Oh Y. Differential effects of IGFBP-3 and its proteolytic fragments on ligand binding, IGFIR signaling and cell surface association. Endocrinology. 2000;141:4171-4179.
37. Devi GR, Oh Y, Rosenfeld RG. Effect of IGFBP-3 on IGF- and IGF-analog-induced IGFIR signaling. Growth Horm. IGF Res. 2001;11:231-239.
38. Summerton J, Weller D. Antisense properties of morpholino oligomers. Nucleosides Nucleotides. 1997;16:889-898.
39. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta. 1999;1489:141-158.
40. Iversen PL. PMO: favorable properties for sequence-specific inactivation. Curr Opin Mol Ther. 2001;3:235-238.
41. Giles RV, Spiller DG, Clark RE, Tidd DM. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acids Drug Dev. 1999;9: 213-220.
42. Ghosh C, Stein D, Weller D, Iversen PL. Evaluation of antisense mechanisms of action. Methods Enzymol. 2000;313:135.
43. Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in Lewis lung carcinoma murine model. Anti-Cancer Drugs. 2003;14:39-47.
44. Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci. 2002;91:1009-1017.
45. Arora V, Hannah TL, Iversen PL, Brand R. Transdermal use of phosphorodiamidate Morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm Res. 2002;19:1465-1470.
46. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acids Drug Dev. 1997;7:503-510.
47. Iversen PL, Cornish KG, Iversen LJ, Mata JE, Bylund DB. Bolus intravenous injection of phosphorothioate oligonucleotides causes hypotension by acting as alpha1-adrenergic receptor antagonists. Toxicol Appl Pharm. 1999;160: 289-296.
48. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochem Biophys Acta. 1999;1489:69-84.